AST-203 / Aptamer Sci, Kolon Life Sci - LARVOL DELTA

AST-203, a novel Trop2-targeting aptamer-drug conjugate, exhibits potent antitumor efficacy for the treatment of solid tumors (AACR 2025) - "Trodelvy, a Trop2-targeting antibody-drug conjugate (ADC) linked to the topoisomerase I inhibitor SN-38, has been approved for the treatment of triple-negative breast cancer. AST-203 shows the potential of a promising next-generation therapeutic for Trop2-positive solid tumors. Its superior efficacy and safety compared to traditional antibody-drug conjugates highlight its potential to improve therapeutic outcomes for Trop2-expressing cancers. These findings underscore AST-203 as a significant advancement in aptamer-based therapeutics."

Clinical • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer • TACSTD2

Aptamer Science and Kolon Pharmaceutical, TROP2 Target Joint Research MOU [Google translation] (Hankyung) - "Aptamer Science announced on the 15th that it signed a memorandum of understanding (MOU) with Kolon Pharmaceutical for joint research and development of 'AST-203', a new pancreatic cancer drug candidate. Through this agreement, the two companies will conduct research and development cooperation to develop AST-203 as a pancreatic cancer treatment and move forward with business cooperation for global technology transfer (license-out)."

Commercial • Oncology • Pancreatic Cancer